INTRODUCTION

Moxetumomab pasudotox (brand name Lumoxiti) is a recombinant immunotoxin consisting of the binding fragment (Fv) of an anti-CD22 antibody fused to PE38 toxin of Pseudomonas exotoxin A. Moxetumomab pasudotox is used for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have already been treated with a purine nucleoside analog and one other treatment.

This plasmid is designed for expressing Moxetumomab pasudotox in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-124
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Moxetumomab pasudotox
Brand Name(s): Lumoxiti
Classification: Monoclonal antibody (mAb)
Target: CD22
Amino Acid Sequence: Identical to DB12688

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Bang S, Nagata S, Onda M, Kreitman RJ, Pastan I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res. 2005 Feb 15;11(4):1545-50.

[2] Getta BM, Park JH, Tallman MS. Hairy cell leukemia: Past, present and future. Best Pract Res Clin Haematol. 2015 Dec;28(4):269-72.

Contact Us